Evaluate HROW stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in HROW? | Glauxie AI

Q: What are the risks of investing in HROW?

Harrow Health, Inc. (HROW) operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector). The company is led by CEO Mark L. Baum. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the... Employees: 373.

Q: How much debt does HROW have?

Review HROW total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is HROW a good long-term investment?

Evaluate HROW as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in HROW?

🦉

Harrow Health, Inc. (HROW)

Company Overview

Sector / IndustryHealthcare / Drug Manufacturers - Specialty & Generic

CEOMark L. Baum

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics,...

Key Executives

Name	Title
Amir W. Shojaei	Chief Scientific Officer
Andrew R. Boll	President, Chief Financial Officer & Corporate Secretary
Brett A. Burrell	Vice President of Legal & Compliance
Kim Barratt	Chief Talent Officer
Mark A. Mannebach	Head of Regulatory Affairs & Pharmacovigilance
Mark L. Baum	CEO, Chairman of the Board & Founder

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

HROW Profile Financials

Is HROW stock safe? How much debt does HROW have? Is HROW a good long-term investment?